Safety of concurrent adjuvant radiotherapy and chemotherapy for locally advanced soft tissue sarcoma

Greto, Daniela; Loi, Mauro; Saieva, Calogero; Muntoni, Cristina; Paoli, Camilla Delli; Becherini, Carlotta; Ciabatti, C.; Perna, Marco; Campanacci, Domenico Andrea; Terziani, Francesca; Beltrami, Giovanni; Scoccianti, Guido; Bonomo, Pierluigi; Meattini, Icro; Desideri, Isacco; Simontacchi, Gabriele; Mangoni, Monica; Livi, Lorenzo

doi:10.1177/0300891618765565

Cited by 5 publications

(2 citation statements)

References 27 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, the preoperative delivery of anthracycline + ifosfamide (AI) and RT was proven to be feasible in an Italian and Spanish Sarcoma Group phase 3 randomized study comparing the use of 3 and 5 cycles of AI [22]. Other single-arm studies are available [23], [24], [25]. However this combination was consistently shown to be more toxic as compared to the administration of AI alone.…”

Section: Discussionmentioning

confidence: 99%

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups

et al. 2019

View full text Add to dashboard Cite

Background Myxoid liposarcoma (ML) exhibits a special sensitivity to trabectedin (T) and radiation therapy (RT). Preclinical data suggest a synergistic effect. We aimed to study safety, feasibility and activity of the administration of pre-operative concurrent T and RT in patients affected by localized resectable ML. Methods Patients received 3 cycles (C) of T in combination with RT (45 Gy) in 25 fractions (1.8 Gy/fraction). Dose Levels for T were: − 1 (1.1 mg/m2), 0 (1.3 mg/m2) and 1 (1.5 mg/m2). Primary endpoint was safety; antitumor activity was assessed by RECIST and Choi criteria. This study is registered at ClinicalTrials.gov , number NCT02275286 . The phase 1 part of the study is complete and phase 2 is ongoing. Findings From February 2015 to May 2016, 14 patients (M/F 7/7), median age 36 years (range 24–70) and median tumor size 12.5 cm (range 7–17 cm), were enrolled. One dose limiting toxicity (G3 transaminitis) occurred at Level 0 and one (sepsis due to catheter infection) at Level 1. All patients completed RT. Five patients achieved PR (36%), 8 SD (57%), 1 distant PD (7%) by RECIST, while 12 achieved PR (86%), 1 SD (7%) and 1 distant PD (7%) by Choi criteria. Twelve patients underwent surgery. Median viable residual tumor was 5% (0–60). Interpretation T in combination with RT showed a favorable safety profile and antitumor activity in localized ML. T dose of 1.5 mg/m2 is the recommended dose for the phase 2 study, which is ongoing. Funding This study was partially supported by Pharmamar.

show abstract

Section: Discussionmentioning

confidence: 99%

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups

et al. 2019

View full text Add to dashboard Cite

show abstract

“…É necessário durante o tratamento estabelecer uma terapia adjuvante eficaz para sarcomas de tecidos moles (STSs), estudos demonstram que a administrado em combinação com quimioterapia à base de doxorrubicina, melhora a eficácia do tratamento (Tian;et al, 2021;Greto;et al,2018).…”

Section: Introductionunclassified

Diagnóstico de miofibrossarcoma de alto grau em cão – relato de caso

Kavasaki

Barboza

Stein

et al. 2021

RSD

View full text Add to dashboard Cite

Os Sarcomas de tecidos moles (STM) na oncologia veterinária, compreendem um grupo de neoplasias mesenquimais malignas, com acometimento principalmente da pele e subcutâneo, possuem margens mal definidas com altos índices de recidiva local e moderado potencial metastático. O diagnóstico de rotina é realizado com base no histórico do animal, sinais clínicos, porém a confirmação é realizada através de exames citológicos e histopatológicos. Complementarmente a quimioterapia, radioterapia e remoção cirúrgica são utilizados para proporcionar uma maior sobrevida aos pacientes. O presente estudo tem por objetivo reportar um caso de Mixofibrossarcoma de Alto Grau, detectado através do exame imuno-histoquimico, uma variação do (STM), em um paciente canino, fila brasileiro, macho, com um ano de idade, atendido em uma clínica veterinária situada no município de Vilhena- Rondônia, apresentando inicialmente um nódulo em região da escápula direita, com evolução rápida e crescimento progressivo após remoção cirúrgica. Os tutores optaram pela eutanásia do animal.

show abstract

Neoadjuvante Strahlentherapie und multimodale radioonkologische Konzepte

Eckert

2020

InFo Hämatol Onkol

View full text Add to dashboard Cite

Safety of concurrent adjuvant radiotherapy and chemotherapy for locally advanced soft tissue sarcoma

Abstract: Concurrent CRT is a well-tolerated treatment option with no additional toxicity compared to exclusive radiotherapy or sequential CRT.

Cited by 5 publications

References 27 publications

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups

Diagnóstico de miofibrossarcoma de alto grau em cão – relato de caso

Neoadjuvante Strahlentherapie und multimodale radioonkologische Konzepte

Contact Info

Product

Resources

About